Ironwood Pharmaceuticals IncIRWD
Price$3.76Intrinsic value$7.82108% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $389.3M+10.8% YoYTTM through 30 Jun 2026
Net Income $129.9M+14,657.7% YoYTTM through 30 Jun 2026
Free Cash Flow $185.4MTTM through 30 Jun 2026

Margins

Current
EBITDA Margin62.8%
Operating Margin68.1%
Net Margin33.4%

Returns

-47.1%ROE
23.5%ROA
27.8%ROIC

Balance Sheet Health

Debt / Equity-2.69x
Current Ratio1.41x
Net Debt$364.4M
Cash & Equivalents$79.1M

Quality Metrics

Altman Z-Score-1.99
Piotroski F-Score6 / 9
FCF Margin47.6%
Rule of 4065.8
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $296.2M
Diluted EPS$0.77TTM
'19'20'21'22'23'24'25
FY2025: $0.15

Dividend

No dividend

Capital Allocation

R&D Spend$88.7M
Capex Intensity0.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.